HALO Mar 2025 35.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 10:17AM EDT
| Previous close | 19.80 |
| Open | 19.80 |
| Bid | 16.60 |
| Ask | 21.00 |
| Strike | 35.00 |
| Expiry date | 2025-03-21 |
| Day's range | 19.80 - 19.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
Investor's Business DailyHow Small Biotech Halozyme, With A 41% Run, Is Getting Under Your Skin
Small biotech company Halozyme is behind some of the biggest names in medicine, including Johnson & Johnson's Darzalex and Roche's Tecentriq.
ZacksWhy This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PR NewswireHalozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received European Commission (EC) marketing authorization of OCREVUS® (ocrelizumab) SC co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
© 2024 Yahoo. All rights reserved.